Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readoutProactive Investors • 04/28/26
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.PRNewsWire • 04/28/26
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst SaysBenzinga • 04/17/26
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon CongletonPRNewsWire • 03/31/26
Immunic secures European patent for MS drug candidate vidofludimus calciumProactive Investors • 03/10/26
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumPRNewsWire • 03/10/26
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 02/26/26
Immunic to raise up to $400M to fund late-stage MS trials, commercial pushProactive Investors • 02/13/26
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage CompanyPRNewsWire • 02/13/26
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MSProactive Investors • 02/04/26